06:30 EDT Lundbeck to acquire Longboard Pharmaceuticals for $60.00 per share, or $2.6B
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals initiates DEEp SEA Study
- Longboard gets Rare Pediatric Disease, Orphan Drug designation for bexicaserin
- 3 Best Stocks to Buy Now, 9/18/2024, According to Top Analysts
- Longboard price target raised to $80 from $60 at H.C. Wainwright
- Longboard treatment of Dravet syndrome granted orphan designation